Brooks Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2024
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brooks Laboratories held its 23rd AGM on September 26, 2025, via video conferencing, and all 8 resolutions put to shareholders were passed. The company had 10,262 shareholders on record, with 96 attending through video conferencing (8 from promoter group, 88 from the public). Routine resolutions—adoption of audited financial statements, reappointment of director Mr. Bhushan Singh Rana, appointment of secretarial auditors, and ratification of cost auditor remuneration—passed with near-unanimous support of over 99.9%. Three special resolutions were also approved: a broad restructuring mandate covering sale, merger, demerger, slump sale or amalgamation (89.19% in favour); disposal or transfer of the company's investment in Brooks Steriscience Limited under any restructuring scheme (98.95% in favour); and alteration of the Memorandum of Association (75.32% in favour). Public non-institutional shareholders showed meaningful dissent on the Related Party Transactions resolution (35% against) and the MOA alteration (93.5% against), though both still passed overall.
This is a routine regulatory filing, but the approved special resolutions give the company significant flexibility to undertake restructuring or divest its Brooks Steriscience stake in the future. The strong public shareholder opposition on the MOA alteration and related party transactions is a red flag that could attract governance scrutiny and may influence minority shareholder sentiment going forward.